Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Sees Significant Decline in Short Interest

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 10,900 shares, a decline of 6.0% from the May 31st total of 11,600 shares. Based on an average trading volume of 11,200 shares, the short-interest ratio is presently 1.0 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Trading of Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Rowlandmiller & PARTNERS.ADV purchased a new stake in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) during the first quarter, according to its most recent filing with the SEC. The fund purchased 14,433 shares of the company’s stock, valued at approximately $108,000. Rowlandmiller & PARTNERS.ADV owned about 0.17% of Cryo-Cell International as of its most recent filing with the SEC. 10.44% of the stock is currently owned by institutional investors.

Cryo-Cell International Price Performance

Shares of CCEL opened at $7.00 on Thursday. Cryo-Cell International has a 52 week low of $3.67 and a 52 week high of $9.50. The stock has a market capitalization of $56.70 million, a price-to-earnings ratio of -6.03 and a beta of 0.47.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its earnings results on Monday, April 15th. The company reported $0.07 earnings per share (EPS) for the quarter. Cryo-Cell International had a negative net margin of 31.02% and a negative return on equity of 64.31%. The company had revenue of $7.85 million during the quarter.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.